[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Nrx Pharmaceuticals Inc (NRXP)

Nrx Pharmaceuticals Inc (NRXP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 160,132
  • Shares Outstanding, K 36,229
  • Annual Sales, $ 1,230 K
  • Annual Income, $ -28,620 K
  • EBIT $ -17 M
  • EBITDA $ -17 M
  • 60-Month Beta 2.02
  • Price/Sales 131.31
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 130.29% (-15.83%)
  • Historical Volatility 117.81%
  • IV Percentile 13%
  • IV Rank 15.90%
  • IV High 734.57% on 02/13/26
  • IV Low 16.06% on 09/08/25
  • Expected Move (DTE 19) 0.85 (19.23%)
  • Put/Call Vol Ratio 0.05
  • Today's Volume 1,390
  • Volume Avg (30-Day) 556
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 14,789
  • Open Int (30-Day) 12,681
  • Expected Range 3.57 to 5.27

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.09
  • Number of Estimates 2
  • High Estimate $-0.05
  • Low Estimate $-0.13
  • Prior Year $-0.98
  • Growth Rate Est. (year over year) +90.82%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.74 +61.31%
on 05/12/26
4.59 -3.60%
on 05/29/26
+1.51 (+51.89%)
since 04/29/26
3-Month
1.62 +172.84%
on 03/09/26
4.59 -3.60%
on 05/29/26
+2.56 (+137.63%)
since 02/27/26
52-Week
1.62 +172.84%
on 03/09/26
4.59 -3.60%
on 05/29/26
+1.83 (+70.66%)
since 05/28/25

Most Recent Stories

More News
NRx Pharmaceuticals (Nasdaq: NRXP) Strategic Partner Emobot Presents Late-Breaking Clinical Validation of the EMOCARE Depression Thermometer at ASCP 2026

EMOCARE is a smartphone-based passive monitoring tool that generates a continuous, real-time measure of depression from patient voice, facial expression, motion, and screen behavior, and is the first passive...

NRXP : 4.42 (-0.45%)
NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Becomes First Commercial Site to Deploy Zeta Surgical's FDA-Cleared Zeta TMS Navigation System

Deployment at HOPE's West Palm Beach clinic brings AI-powered, sub-millimetric image guidance to the delivery of Transcranial Magnetic Stimulation (TMS) for patients with Major Depressive Disorder and...

NRXP : 4.42 (-0.45%)
NRx Pharmaceuticals Q1 Earnings Call Highlights

NRx Pharmaceuticals (NASDAQ:NRXP) said it advanced several regulatory, manufacturing and clinical initiatives during the first quarter of 2026, including progress toward potential approval of its preservative-free...

NRXP : 4.42 (-0.45%)
NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2026 Financial Results and Provides Corporate Update

Key highlights from the first quarter of operations under the expanded management team include the following: Anticipated FDA decision on the Company's ANDA for Preservative-Free Ketamine in Q3 2026,...

NRXP : 4.42 (-0.45%)
New to The Street's Show #753 Airs Nationwide on Bloomberg Television Across the U.S., MENA and Latin America Featuring FreeCast (NASDAQ:CAST), Stardust Power (NASDAQ:SDST), Lost Soldier Oil and Gas, Virtuix Holdings (NASDAQ:VTIX), and Medicus Pharma

The show broadcasts as sponsored programming featuring TV commercials from IGC Pharma, Inc. (NYSE American:IGC), NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), Medicus Pharma Ltd. (NASDAQ:MDCX), and DataVault...

CAST : 0.8290 (+0.69%)
SDST : 2.28 (-4.60%)
IGC : 0.2889 (-0.28%)
VTIX : 3.70 (+2.78%)
MDCX : 0.3790 (+15.09%)
NRXP : 4.42 (-0.45%)
DVLT : 0.5000 (+0.58%)
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report First Quarter 2026 Financial Results and Provide Corporate Update

WILMINGTON, Del., May 14, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, the “Company”), a clinical-stage biopharmaceutical company, today announced...

NRXP : 4.42 (-0.45%)
NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Clearance to Proceed with Clinical Trial of NRX-101 in Combination with Robotic-enabled Transcranial Magnetic Stimulation in Patients with Depression and Suicidality

Preliminary research suggests that D-cycloserine significantly enhances the effect of Transcranial Magnetic Stimulation (TMS) Trial is planned to be conducted at a leading US academic teaching hospital,...

NRXP : 4.42 (-0.45%)
NRx Pharmaceuticals (NASDAQ: NRXP) Initiates First Commercial Manufacturing Order For Preservative-Free Ketamine

NRx Pharmaceuticals (NASDAQ: NRXP) announced it has initiated its first commercial manufacturing order of preservative-free ketamine in anticipation of potential approval under the Generic Drug User Fee...

NRXP : 4.42 (-0.45%)
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Initiation of Commercial Manufacturing for Preservative Free Ketamine

Based on FDA Office of Generic Drugs guidance previously announced, NRx has transmitted an initial GMP manufacturing order to its US-based manufacturer. NRx has completed confirmatory GMP audits of manufacture...

NRXP : 4.42 (-0.45%)
GLOBAL MARKETS SPOTLIGHT: New to The Street Show #748 Delivers High-Impact CEO Interviews and Spotlight TV Commercials Across Bloomberg to 250M+ Households Worldwide

NEW YORK, NY / ACCESS Newswire / May 1, 2026 / New to The Street, one of the longest-running business television brands, today announced the nationwide broadcast of Show #748 airing Saturday, May 2 at...

RDZN : 1.8800 (+0.53%)
SNYR : 0.2690 (-3.31%)
IGC : 0.2889 (-0.28%)
VTIX : 3.70 (+2.78%)
NRXP : 4.42 (-0.45%)
MDCX : 0.3790 (+15.09%)
YYGH : 0.1900 (-18.10%)
DVLT : 0.5000 (+0.58%)
CISO : 0.4454 (+6.05%)

Business Summary

NRX Pharmaceuticals Inc. is a patient-focused, clinical stage pharmaceutical company. It creates therapies to treat diseases where no medicines currently exist. NRX Pharmaceuticals Inc., formerly known as Big Rock Partners Acquisition Corp., is based in RADNOR, Pa.

See More

Key Turning Points

3rd Resistance Point 4.87
2nd Resistance Point 4.73
1st Resistance Point 4.57
Last Price 4.42
1st Support Level 4.28
2nd Support Level 4.14
3rd Support Level 3.99

See More

52-Week High 4.59
Last Price 4.42
Fibonacci 61.8% 3.45
Fibonacci 50% 3.10
Fibonacci 38.2% 2.75
52-Week Low 1.62

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.